STAT+: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025
STAT
APRIL 11, 2024
billion in 2025, a spokesperson for the Centers for Medicare and Medicaid Services confirmed to STAT. Medicare’s actuaries expect the drug Leqembi , made by the Japanese drugmaker Eisai and sold in partnership with Biogen, to cost the traditional Medicare program around $550 million in 2024, and the entire Medicare program $3.5
Let's personalize your content